Current antimalarials often fail to target mature stage V gametocytes. To aid antimalarial drug discovery, the authors present a preclinical malaria transmission-blocking drug research platform, using engineered parasites, that facilitates the screening for gametocytocidal compounds in vitro and the evaluation of transmission-blocking drug activity in vivo.

ObjectiveTo assess the competence of students and academic staff to use generative artificial intelligence (GenAI) as a tool in epidemiological data analyses...

The Biomolecular Screening Facility has contributed to a successful collaborative study led by Till Voss (Swiss Tropical and Public Health Institute, University of Basel), resulting in the development of a robust, all in one pipeline for the discovery and testing of transmission blocking drugs against Plasmodium falciparum. This multidisciplinary effort combines a high-throughput in vitro assay with a novel in vivo model, enabling systematic evaluation of compounds that target mature stage V gametocytes - the only forms of the parasite that infect mosquitoes.

With the start of the autumn semester, Swiss TPH warmly welcomes over 90 new master’s and PhD students from across the globe. The number of master’s students increased over the last years, reflecting ...

Release of OpenMalaria version 48.0. Update to version 48.0: https://github.com/SwissTPH/openmalaria/wiki/SchemaUpdateGuide Changelog: https://github.com/SwissTPH/openmalaria/wiki/Changelog Example...

Der Rückzug der USA aus der Finanzierung globaler Gesundheitsprogramme setzt Menschenleben aufs Spiel. Auch die Schweiz wird die Folgen spüren – und sollte darum ihre Führungsrolle verstärken.

Eva Herzog, President of the Swiss TPH Board of Governors, reflects why it's time for Switzerland to lead and not retreat in global health.

Routine testing for Legionella in hospitalised pneumonia patients leads to faster diagnosis and better-targeted treatment, according to a new study led by the Swiss Tropical and...